Health
Microba Announces Landmark GI Study Results From Over 4,600 Patients
BRISBANE, Australia, May 15, 2025--Microba Life Sciences Limited (ASX: MAP) ("Microba" or the "Company"), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address un
About this update from Microba Life Sciences Limited
[{"type":"image","alt":"71.4% of MetaXplore™ reports from 4,616 patients identified actionable results","displaySize":"","headline":null,"caption":"71.4% of MetaXplore™ reports from 4,616 patients identified actionable results","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":284,"url":"https://media.zenfs.com/en/business-wire.com/d1b5f0edff276545623297ca356b491b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/SVyXfyMsR6R4Zx1uZ0YUMg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU2ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d1b5f0edff276545623297ca356b491b","width":480,"height":284}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/e488f7b9e7ffe627f20115488bc61f2f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/alZsAIlbYY7M_Fck6InbJA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/e488f7b9e7ffe627f20115488bc61f2f","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/8cgx8RvuTJNwsT_dHxIeOw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/e488f7b9e7ffe627f20115488bc61f2f","width":1024,"height":512}}},{"type":"text","content":"Results at a glance:","length":20,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"71.4% of MetaXplore™ reports from 4,616 patients identified actionable results","length":78,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"41.9% tested positive for abnormal microbiome markers linked to gastrointestinal health","length":87,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"9.9% tested positive for gastrointestinal markers, including inflammation, pancreatic insufficiency, or blood in stool","length":118,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"19.6% of reports tested positive for multiple markers (microbiome and gastrointestinal)","length":87,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"65% of patients reported health improvements following clinician-directed recommendations informed by MetaXplore","length":112,"tagName":"p","attribs":{}}]}],"tagName":"ul","bull...